BioSpace News Archive

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2021.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced that management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.

Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to NXP800 has been selected for an oral presentation and an abstract related to NXP900 has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Meeting.

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), today announced that it has signed an agreement with Cervos Inc. (“Cervos Medical”) to become the exclusive distributor of Marrow Cellution™ devices for use in urology, gynecology, and male and female sexual dysfunction.

The global dental services market size is expanding over US$ 698.8 billion by 2030 from at US$ 371.4 billion in 2020, poised to grow at a CAGR of 6.4% from 2021 to 2030.

The global medical tourism market growth is expanding at a remarkable CAGR of around 10.8% during the forecast period 2021 to 2030 due to increased demand for the cheap treatment for various chronic diseases.

Increasing volumes of newborn screening tests to check for metabolic, genetic abnormalities, or developmental problems are expected to drive the global market revenue growth.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference.

Rising number of cancer cases worldwide and increasing spending by governments of various countries globally on cancer research & development are factors driving market revenue growth.